Intas Pharma launches biosimilar in Europe

Intas Pharmaceuticals has launched its biosimilar product, filgrastim, in the European market under the brand Accofil, which is a biosimilar product of Neupogen made by Amgen. It is used in the treatment of immune system disorders such as neutropenia and is used to treat patients with advanced HIV infection.

After winning two tenders, the product has been launched in the Netherlands and the U.K. through Intas’ subsidiary Accord Healthcare. "This is only the first of many biological products that we will launch in the EU and other regulated markets over the next few years,’’ Intas Vice Chairman Binish Chudgar said in a statement.

“The product was developed as per our original agreement with our collaborator, Apotex,’’ Rajiv Malik, Executive Vice President, Business Development and Licensing, Intas, told this correspondent, adding that the market for size of filgrastim in Europe was $400 million. The global market for the product was $1.8 billion, Mr. Malik said. He said the injectible product would be priced competitively, and had added safety and packaging features and unlike other biosimilars in the market, it would remain stable even at room temperature.

Accofil was developed at Intas’ laboratories and is made at its cGMP approved facility in Ahmedabad. "The same facility will be used to make the products for the U.S. and other regulated markets. We will launch in Mexico in the next six months and Brazil and the U.S. in about a year after Sandoz launches its first biosimilar in the U.S. this year,’’ Mr. Malik said.

Intas is a leading player in biosimilars in India having launched its first product in the domestic market in 2004.

Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Jul 5, 2022 6:16:52 am |